46.22
+0.145(+0.31%)
Currency In USD
| Previous Close | 46.07 |
| Open | 45.91 |
| Day High | 46.6 |
| Day Low | 45.49 |
| 52-Week High | 62.4 |
| 52-Week Low | 29.17 |
| Volume | 891,651 |
| Average Volume | 2.27M |
| Market Cap | 8.64B |
| PE | -10.22 |
| EPS | -4.52 |
| Moving Average 50 Days | 39.34 |
| Moving Average 200 Days | 39.73 |
| Change | 0.14 |
If you invested $1000 in Revolution Medicines, Inc. (RVMD) since IPO date, it would be worth $1,599.13 as of September 30, 2025 at a share price of $46.215. Whereas If you bought $1000 worth of Revolution Medicines, Inc. (RVMD) shares 3 years ago, it would be worth $2,343.56 as of September 30, 2025 at a share price of $46.215.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
GlobeNewswire Inc.
Sep 10, 2025 8:02 PM GMT
Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability Highly encouraging initial clinical results for daraxonrasib monotherapy and daraxo
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
GlobeNewswire Inc.
Jul 30, 2025 8:05 PM GMT
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report fina